Duragesic, Generics May Warrant Risk Management Plans, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will continue to monitor incidents of abuse or misuse of fentanyl transdermal systems and "may consider" requesting brand and generic manufacturers to implement a voluntary risk management plan, FDA says in denying citizen petition requests to delay approval of Duragesic generics.
You may also be interested in...
Lavipharm Transdermal Fentanyl Patch Generic Approved By FDA
Greek drug maker said it plans to launch the generic of J&J/Alza's Duragesic patch with a U.S. partner, which it has yet to announce.
Lavipharm Transdermal Fentanyl Patch Generic Approved By FDA
Greek drug maker said it plans to launch the generic of J&J/Alza's Duragesic patch with a U.S. partner, which it has yet to announce.
FDA Examining Citizen Petition Review Process To Speed Generic Approvals
The agency is looking at its review process for citizen petitions to expedite decisionmaking, but FDA has not settled on a course of action, Acting Commissioner Crawford and CDER Acting Director Galson tell GPhA. Citizen petitions have “got me losing sleep at night,” OGD Director Buehler says.